|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The purpose of the study is to identify the Cancer Stem Cells (CSCs) and to determine their expression profiles in different pathological stages of liver cancer by using multiple markers Methods: In this study, the expression profiles of CD133 and CD13, along with those of stem cell markers Oct4 and SOX2, were analyzed using immunohistochemistry and immunoblotting to clarify the character of CSCs in different stages of liver cancer.
|
31646784 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this cohort study, a CGP named NCC-GP150 was designed and virtually validated using The Cancer Genome Atlas database.
|
30816954 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, we first applied an aminopeptidase N (APN)-sensitive probe based on PET for cancer diagnosis and therapy.
|
31538473 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ubenimex, an aminopeptidase N (APN) inhibitor, is widely known for its use as an adjunct therapy for cancer therapy.
|
31571825 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Aminopeptidase M (AMP) inhibition is of interest for several diseases, such as highly vascularized cancer types.
|
31795383 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
APN is thought to be a very important target for cancer therapy as it is linked to cancer progression and metastasis.
|
31126854 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation.
|
30198568 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The present review describes the recent advances on the involvement of APN and its receptors in the etiology of different types of cancer.
|
30781341 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of the present review is to summarize the currently available evidence on the involvement of APN and its signaling in the etiology of cancer, focusing on endocrine malignancies.
|
31212761 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The serum IL-4 and IL-10 levels in patients with postoperative infection of colorectal cancer are positively correlated with the stage of cancer, while the serum APN level was negatively correlated with the stage of cancer.
|
30675219 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Plasma APN and cancer mortality have a significant relationship among community-dwelling elderly people, which warrants further study.
|
29576602 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Molecular Imaging of Aminopeptidase N in Cancer and Angiogenesis.
|
30046296 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cytotoxic effect of the synthesized compounds was evaluated against a group of cancer cell lines, including MCF-7, A2780 (α<sub>v</sub>β<sub>3</sub> positive), OVCAR3 (high α<sub>v</sub>β<sub>3</sub>), HT-1-80 (high CD13) and SKOV-3 (CD13 positive).
|
30568688 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, APN inhibitors may be useful for the treatment of cancer.
|
29630364 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It may be inferred from these studies that the three radiotracers are promising probes for in vivo imaging of CD13 receptor expressing cancer sites; however, <sup>68</sup> Ga-NODAGA-c(NGR) is a better candidate.
|
29130625 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ubenimex, an Aminopeptidase N (APN) inhibitor, is now widely used for cancer as an adjunct therapy, conferring antitumor effects.
|
29503569 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD13 represents a potential therapeutic target for HCC, because CSC regulation and EMT suppression are essential in cancer therapy.
|
29145632 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, NGR peptides can precisely deliver therapeutic and diagnostic compounds to CD13 expressing cancer sites.
|
29139598 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Investigating the molecular signaling pathways using CD13 as a marker for Cancer Stem Cells (CSCs) in human liver cancer.
|
29630108 |
2018 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The proteolytic activity of APN promotes cancer angiogenesis and metastasis making it an important target for cancer therapy.
|
28465619 |
2017 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
An increased expression of APN has been described in several types of human malignancies, especially those characterized by fast-growing and aggressive phenotypes, suggesting APN as a potential therapeutic target.
|
29029544 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These nanomaterials with non-toxic concentrations could cross the BBB and target CD13-overexpressing glioma and tumor vasculature in vitro and in vivo, contributing to fluorescence imaging of this brain malignancy.
|
27682740 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, inhibitors of APN may be effective against cancer and inflammation.
|
28964831 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis.
|
27991698 |
2017 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The ADIPOQ rs266729 G/C gene polymorphism is significantly associated with low APN levels and linked to susceptibility to develop cancer.
|
28529612 |
2017 |